Wiley Partners With OpenEvidence to Integrate Peer-Reviewed Medical Content Into Clinical AI Platform

Under the agreement, clinicians using OpenEvidence will be able to access evidence from hundreds of Wiley journals and reference works across multiple medical specialties.

Academic publisher Wiley has partnered with clinical artificial intelligence platform OpenEvidence to integrate a large portfolio of peer-reviewed medical and scientific content into the AI tool used by physicians at the point of care.

Under the agreement, clinicians using OpenEvidence will be able to access evidence from hundreds of Wiley journals and reference works across multiple medical specialties. The integration is designed to support physicians with evidence-based insights during clinical decision-making.

The partnership comes amid growing attention across healthcare and scholarly publishing sectors on ensuring that AI systems used in clinical environments rely on authoritative research rather than unverified web sources.

Medical knowledge is estimated to double every 73 days, yet research findings often take years to influence clinical practice. According to industry estimates cited by the companies, it takes an average of 17 years for a portion of published research to translate into routine patient care.

Daniel Nadler, founder of OpenEvidence, said the partnership aims to help reduce that lag by connecting clinicians with verified medical research through AI systems trained on peer-reviewed literature.

“The hard problem in medicine right now isn’t just generating new knowledge. We are living through a golden age of biomedical research,” Nadler said. “The hard problem is also that it takes 17 years for a fraction of that research to reach the bedside. Wiley is an ideal partner in solving this problem for physicians.”

As part of the licensing agreement, Wiley will provide OpenEvidence with access to a portfolio of scientific and medical resources. These include the Cochrane Database of Systematic Reviews and Cochrane Clinical Answers, which offer evidence syntheses and clinical insights derived from systematic reviews used in guideline development.

Karla Soares-Weiser, CEO of Cochrane, said the collaboration reflects broader shifts in how healthcare professionals access medical evidence.

“AI is rapidly changing the ways that people use and access evidence, and we hope that this partnership helps to ensure that outputs from AI-powered tools are based on the best possible evidence,” she said.

The licensed portfolio will also include more than 400 Wiley journals and books, along with reference titles such as Holland-Frei Cancer Medicine, Rook’s Dermatology Handbook, and Yamada’s Textbook of Gastroenterology. The resources span specialties including cardiology, endocrinology, geriatrics, hematology, neurology, oncology, psychiatry, and rheumatology.

According to the companies, the content will be incorporated into OpenEvidence’s evidence layer and cited within AI-generated responses. The platform reports that it is currently used by more than 40% of physicians in the United States.

Stay tuned for more such updates on Digital Health News